Turnstone Narrows Q2 Loss Amid R&D Cuts, Cash Declines

TL;DR

**Turnstone's cash burn is concerning, signaling a need for capital or a major clinical win soon.**

AI Summary

Turnstone Biologics Corp. reported a net loss of $29.9 million for the three months ended June 30, 2025, a slight improvement from the $30.1 million net loss in the prior-year period. For the six months ended June 30, 2025, the net loss was $60.1 million, compared to $59.8 million for the same period in 2024. Research and development expenses decreased to $23.1 million for the three months ended June 30, 2025, from $24.2 million in the prior year, primarily due to reduced clinical trial costs for TIDAL-01. General and administrative expenses increased to $7.0 million for the three months ended June 30, 2025, from $6.0 million in the prior year, driven by higher personnel-related costs and professional fees. The company's cash and cash equivalents, restricted cash, and marketable securities totaled $105.3 million as of June 30, 2025, down from $135.2 million at December 31, 2024. Turnstone continues to advance its clinical programs, including TIDAL-01, and manage its contingent consideration liabilities related to the Myst merger agreement, which stood at $10.0 million as of June 30, 2025.

Why It Matters

Turnstone Biologics' continued net losses and declining cash reserves signal ongoing financial pressure, which could impact its ability to fund critical clinical trials for investors. For employees, this financial strain might lead to future workforce adjustments or a slower pace of drug development. Customers awaiting innovative cancer therapies could face delays if funding becomes a bottleneck. In the competitive oncology market, Turnstone's financial health is crucial for maintaining its position against larger, better-capitalized biopharmaceutical companies, especially as it navigates the expensive late-stage clinical development of candidates like TIDAL-01.

Risk Assessment

Risk Level: high — The company reported a net loss of $60.1 million for the six months ended June 30, 2025, and its cash, restricted cash, and marketable securities decreased by $29.9 million to $105.3 million from December 31, 2024. This significant cash burn, coupled with ongoing losses, indicates a high risk of needing additional financing in the near future, which could dilute existing shareholder value.

Analyst Insight

Investors should closely monitor Turnstone's cash runway and upcoming clinical trial milestones for TIDAL-01. Consider reducing exposure if the company fails to secure additional funding or report positive clinical data within the next 12-18 months, as dilution or operational slowdowns are likely.

Financial Highlights

net Income

-$29.9M

cash Position

$105.3M

Key Numbers

• $29.9M — Net Loss (Q2 2025) (Slight improvement from $30.1M in Q2 2024)
• $60.1M — Net Loss (YTD Q2 2025) (Compared to $59.8M in YTD Q2 2024)
• $23.1M — Research and Development Expense (Q2 2025) (Decreased from $24.2M in Q2 2024 due to reduced TIDAL-01 costs)
• $7.0M — General and Administrative Expense (Q2 2025) (Increased from $6.0M in Q2 2024 due to higher personnel and professional fees)
• $105.3M — Cash, Restricted Cash, and Marketable Securities (June 30, 2025) (Decreased from $135.2M at December 31, 2024)
• $10.0M — Contingent Consideration (June 30, 2025) (Related to the Myst merger agreement)

Key Players & Entities

• Turnstone Biologics Corp. (company) — filer of the 10-Q
• Myst (company) — entity involved in a merger agreement with contingent consideration
• TIDAL-01 (other) — lead clinical program
• H. Lee Moffitt Cancer Center (company) — partner in an alliance agreement
• Langer (person) — recipient of milestone payments
• SEC (regulator) — recipient of the 10-Q filing
• Bloomberg (company) — publisher of the analysis

FAQ

Risk Factors

• Cash Burn Rate and Future Funding Needs [high — financial]: The company reported $105.3 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2025, a decrease from $135.2 million at the end of 2024. This reduction indicates a significant cash burn rate, which, if continued, could necessitate future financing rounds that may dilute existing shareholders or impact operational flexibility.
• Contingent Consideration Liabilities [medium — financial]: Turnstone has $10.0 million in contingent consideration liabilities related to the Myst merger agreement as of June 30, 2025. The payment of this consideration is contingent on specific future events, and any failure to meet these milestones could lead to disputes or impact the company's financial obligations.
• Clinical Trial Execution and Costs [high — operational]: While R&D expenses decreased to $23.1 million in Q2 2025 from $24.2 million in Q2 2024, primarily due to reduced clinical trial costs for TIDAL-01, ongoing clinical trials remain a significant operational and financial undertaking. Delays or unexpected results in these trials could materially impact the company's development timelines and future prospects.
• Increasing General and Administrative Expenses [medium — operational]: G&A expenses rose to $7.0 million in Q2 2025 from $6.0 million in Q2 2024, driven by higher personnel-related costs and professional fees. This upward trend in overhead, if not managed effectively, could further strain financial resources and impact profitability.

Industry Context

Turnstone Biologics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel cancer immunotherapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight from bodies like the FDA. Success hinges on clinical trial outcomes, intellectual property protection, and the ability to secure substantial funding for ongoing research and commercialization efforts.

Regulatory Implications

As a biotechnology company, Turnstone is subject to rigorous regulatory scrutiny from agencies such as the FDA. Approval pathways for novel therapies are complex and lengthy, and any setbacks in clinical trials or manufacturing can lead to significant delays and increased costs. Compliance with evolving regulatory standards for drug development and marketing is critical for market access and long-term viability.

What Investors Should Do

1. Monitor cash burn rate and future financing plans.
2. Track progress and milestones for TIDAL-01.
3. Evaluate the impact of increasing G&A expenses.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing net loss of $29.9M and cash balance of $105.3M.
• 2025-08-08: Filing Date of 10-Q — Indicates the official release of the company's financial performance and disclosures for the period ending June 30, 2025.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of cash position, which decreased from $135.2M to $105.3M by June 30, 2025.

Glossary

Contingent Consideration

An obligation to transfer additional assets or equity interests to the seller of a business in the future as part of the purchase price, contingent upon the occurrence of specified future events. (Turnstone has $10.0 million in contingent consideration related to the Myst merger, representing a potential future financial obligation.)

TIDAL-01

A specific clinical program or drug candidate being developed by Turnstone Biologics. (Reduced clinical trial costs for TIDAL-01 contributed to a decrease in R&D expenses for the quarter.)

Myst merger agreement

An agreement governing the merger between Turnstone Biologics and another entity named Myst. (This agreement is the source of the company's contingent consideration liabilities.)

Year-Over-Year Comparison

Turnstone Biologics reported a net loss of $29.9 million for Q2 2025, a slight improvement from $30.1 million in the prior year's quarter, but the year-to-date net loss widened slightly to $60.1 million from $59.8 million. Research and development expenses saw a decrease to $23.1 million due to lower clinical trial costs for TIDAL-01, while general and administrative expenses increased to $7.0 million driven by higher personnel and professional fees. The company's cash position has declined from $135.2 million at the end of 2024 to $105.3 million as of June 30, 2025.

Key Financial Figures

• $0.001 — e on which registered Common Stock ($0.001 par value) TSBX Nasdaq Capital Mark

Filing Documents

• tsbx-20250630.htm (10-Q) — 1997KB
• tsbx-ex10_1.htm (EX-10.1) — 374KB
• tsbx-ex31_1.htm (EX-31.1) — 15KB
• tsbx-ex31_2.htm (EX-31.2) — 15KB
• tsbx-ex32_1.htm (EX-32.1) — 10KB
• 0000950170-25-105957.txt ( ) — 10147KB
• tsbx-20250630.xsd (EX-101.SCH) — 1506KB
• tsbx-20250630_htm.xml (XML) — 1934KB

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (unaudited) 2 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (unaudited) 4 Notes to Condensed Consolidated Financial Statements (unaudited) 5 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4

Controls and Procedures

Controls and Procedures 31 PART II OTHER INFORMATION Item 1

Legal Proceedings

Legal Proceedings 32 Item 1A

Risk Factors

Risk Factors 32 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3 Defaults Upon Senior Securities 34 Item 4 Mine Safety Disclosures 34 Item 5 Other Information 34 Item 6 Exhibits 35 Signature 36 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties, many of which are beyond our control. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements as a result of various factors, including those set forth below under the caption "Risk Factors." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations and financial condition. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2024, or Annual Report, an

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATE MENTS

ITEM 1. FINANCIAL STATE MENTS Turnstone Biologics Corp. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) June 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 16,688 $ 28,926 Restricted cash 1,906 116 Property and equipment held for sale 313 — Prepaid expenses 366 3,191 Operating lease right of use assets, current 265 — Other current assets 1,571 1,987 Total current assets 21,109 34,220 Other assets, noncurrent — 811 Operating lease right of use assets — 933 Property and equipment, net — 4,175 Total assets $ 21,109 $ 40,139 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,687 $ 870 Accrued expenses and other current liabilities 3,247 6,244 Operating lease liability, current 411 1,085 Total current liabilities 6,345 8,199 Operating lease liability, noncurrent — 104 Other liabilities, noncurrent — 369 Total liabilities 6,345 8,672 Stockholders' equity Preferred stock, $ 0.001 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively, 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.001 par value; 490,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively, 23,140,691 and 23,136,617 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 23 23 Additional paid-in capital 279,834 279,241 Accumulated other comprehensive loss ( 202 ) ( 202 ) Accumulated deficit ( 264,891 ) ( 247,595 ) Total stockholders' equity 14,764 31,467 Total liabilities and stockholders' equity $ 21,109 $ 40,139 The accompanying notes area an integral part of these unaudited condensed consolidated financial statements. 1 Turnstone Biologics Cor

View Full Filing

View this 10-Q filing on SEC EDGAR